Chronic lymphocytic leukemia

New England Journal of Medicine

Volumn 352, Issue 8, 2005, Pages

  Chiorazzi, Nicholas ^a,b,g   Rai, Kanti R ^a,c,d   Ferrarini, Manlio ^e,f  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; PROTEIN KINASE ZAP 70; LYMPHOCYTE ANTIGEN RECEPTOR;

B LYMPHOCYTE; CANCER GROWTH; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ACTIVITY; DISEASE COURSE; DRUG TARGETING; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HYPOTHESIS; IMMUNOGLOBULIN GENE; IMMUNOSTIMULATION; LEUKEMIA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; CANCER STAGING; CELL TRANSFORMATION; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTE ACTIVATION; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 13844307760     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra041720     Document Type: Review

References (122)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-7. [Erratum, N Engl J Med 1995;333:1515.]
2. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-7. [Erratum, N Engl J Med 1995;333:1515.]
3. Dameshek W. Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood 1967;29:Suppl:566-84.
4. Patel DV, Rai KR, Chronic lymphocytic leukemia. In: Hoffman R, Benz EJ, Shattil SJ, et al., eds. Hematology, principles and practice. 4th ed. Philadelphia: Elsevier Churchill Livingstone, 2005:1437-54.
5. Kelsoe G. B cell diversification and differentiation in the periphery. J Exp Med 1994;180:5-6.
6. de Vinuesa CG, Cook MC, Ball J, et al. Germinal centers without T cells. J Exp Med 2000;191:485-94.
7. Monson NL, Foster SJ, Brezinschek HP, Brezinschek RI, Dorner T, Lipsky PE. The role of CD40-CD40 ligand (CD154) interactions in immunoglobulin light chain repertoire generation and somatic mutation. Clin Immunol 2001;100:71-81.
8. Weller S, Faili A, Garcia C, et al. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A 2001;98:1166-70.
9. Toellner KM, Jenkinson WE, Taylor DR, et al. Low-level hypermutation in T cell-independent germinal centers compared with high mutation rates associated with T cell-dependent germinal centers. J Exp Med 2002;195:383-9.
10. William J, Euler C, Christensen S, Shlomchik MJ. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 2002;297:2066-70.
11. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998;160:395-402.
12. Lund FE, Yu N, Kim KM, Reth M, Howard MC. Signaling through CD38 augments B cell antigen receptor (BCR) responses and is dependent on BCR expression. J Immunol 1996;157:1455-67.
13. Zupo S, Massara R, Dono M, et al. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 2000;95:1199-206.
14. Niiro H, Clark EA. Regulation of B-cell rate by antigen-receptor signals. Nat Rev Immunol 2002;2:945-56.
15. Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992;71:649-62.
16. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-5.
17. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378-82.
18. Ternynck T, Dighiero G, Follezou J, Binet JL. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. I. Detection and quantitation of light chain determinants. Blood 1974;43:789-95.
19. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
20. Rai K. A critical analysis of staging in CLL. In: Gale RP, Rai KR, eds. Chronic lymphocytic leukemia: recent progress, future direction. New York: Alan R, Liss, 1987:253.
21. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
22. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994;15:288-94.
23. Hashimoto S, Dono M, Wakai M, et al. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells. J Exp Med 1995;181:1507-17.
24. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997;89:4153-60.
25. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-25.
26. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
27. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-6.
28. Zupo S, Isnardi L, Megna M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996;88:1365-74.
29. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
30. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181-6.
31. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001;115:854-61.
32. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
33. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609-14.
34. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51.
35. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-11.
36. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
37. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
38. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-38.
39. Maloum K, Davi F, Merle-Beral H, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 2000;96:377-9.
40. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-9.
41. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-84.
42. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003;21:841-94.
43. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103:4389-95.
44. Thunberg U, Johnson A, Roos G, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001;97:1892-4.
45. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:1262-9.
46. Kong GH, Bu JY, Kurosaki T, Shaw AS, Chan AC. Reconstitution of Syk function by the ZAP-70 protein tyrosine kinase. Immunity 1995;2:485-92.
47. Dalla-Favera R, Gaidano G. Molecular biology of lymphomas. 6th ed. Philadelphia: Lippincott, 2001.
48. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
49. Migliazza A, Bosch F, Komatsu H, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001;97:2098-104.
50. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Nad Acad Sci U S A 2002;99:15524-9.
51. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31.
52. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004;101:11755-60.
53. Stilgenbauer S, Lichter P, Dohner H. Genomic aberrations in B cell chronic lymphocytic leukemia. In: Cheson BD, ed. Chronic lymphoid leukemias. 2nd ed. New York: Marcel Dekker, 2001:353-76.
54. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A 1994;91:12530-4.
55. Narducci MG, Pescarmona E, Lazzeri C, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 2000;60:2095-100.
56. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A 2002;99:6955-60.
57. Messmer BT, Albesiano E, Messmer D, Chiorazzi N. The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. Blood 2004;103:3490-5.
58. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997;158:235-46.
59. Widhopf GF II, Kipps TJ. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol 2001;166:95-102.
60. Potter KN, Orchard J, Critchley E, Mockridge CI, Jose A, Stevenson FK. Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. Blood 2003;101;3082-4.
61. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262-4.
62. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted V{lambda}2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101:4952-7.
63. Ghiotto F, Fais F, Valette A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004;113:1008-16.
64. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a key role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200:519-25.
65. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2879-85.
66. Widhopf GF II, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004;104:2499-504.
67. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT lymphomas. Hematology (Am Soc Hematol Educ Program) 2001:241-58.
68. Broker BM, Klajman A, Youinou P, et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1988;1:469-81.
69. Sthoeger ZM, Wakai M, Tse DB, et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 1989;169:255-68.
70. Borche L, Lim A, Binet JL, Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990;76:562-9.
71. Schwartz RS, Stollar BD. Heavy-chain directed B-cell maturation: continuous clonal selection beginning at the pre-B cell stage. Immunol Today 1994;15:27-32.
72. Diaw L, Magnac C, Pritsch O, Buckle M, Alzari PM, Dighiero G. Structural and affinity studies of IgM polyreactive natural autoantibodies. J Immunol 1997;158:968-76.
73. Dighiero G, Rose NR, Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity. Immunol Today 1999;20:423-8.
74. Harindranath N, Goldfarb IS, Ikematsu H, et al. Complete sequence of the genes encoding the VH and VL regions of low- and high-affinity monoclonal IgM and IgA1 rheumatoid factors produced by CD5+ B cells from a rheumatoid arthritis patient. Int Immunol 1991;3:865-75.
75. Dameshek W, Schwartz RS. Leukemia and autoimmunization-some possible relationships. Blood 1959;14:1151-8.
76. Casola S, Otipoby KL, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol 2004;5:317-27.
77. Monroe JG. Ligand-independent tonic signaling in B-cell receptor function. Curr Opin Immunol 2004;16:288-95.
78. Hivroz C, Grillot-Courvalin C, Brouet JC, Seligmann M. Heterogeneity of responsiveness of chronic lymphocytic leukemic B cells to B cell growth factor or interleukin 2. Eur J Immunol 1986;16:1001-4.
79. Karray S, Merle-Beral H, Vazquez A, Gerard JP, Debre P, Galanaud P. Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal. Blood 1987;70:1105-10.
80. Michel F, Merle-Beral H, Legae E, Michel A, Debre P, Bismuth G. Defective calcium response in B-chronic lymphocytic leukemia cells: alteration of early protein tyrosine phosphorylation and of the mechanism responsible for cell calcium influx. J Immunol 1993;150:3624-33.
81. Lankester AC, van Schijndel GM, van der Schoot CE, van Oers MH, van Noesel CJ, van Lier RA. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood 1995;86:1090-7.
82. Zupo S, Cutrona G, Mangiola M, Ferrarini M. Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. Blood 2002;99:2277-8.
83. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101:1087-93.
84. Payelle-Brogard B, Magnac C, Alcover A, Roux P, Dighiero G. Defective assembly of the B-cell receptor chains accounts for its low expression in B-chronic lymphocytic leukaemia. Br J Haematol 2002;118:976-85.
85. Payelle-Brogard B, Magnac C, Oppezzo P, Dumas G, Dighiero G, Vuillier F. Retention and defective assembly of the B-cell receptor in the endoplasmic reticulum of chronic lymphocytic leukaemia B cells cannot be reverted upon CD40 ligand stimulation. Leukemia 2003;17:1196-9.
86. Alfarano A, Indraccolo S, Circosta P, et al. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 1999;93:2327-35.
87. Gordon MS, Kato RM, Lansigan F, Thompson AA, Wall R, Rawlings DJ. Aberrant B cell receptor signaling from B29 (Ig-beta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. Proc Natl Acad Sci U S A 2000;97:5504-9.
88. Mangiola M, Cutrona G, Colombo M, et al. Mechanisms that control cell apoptosis or survival through surface Ig in B-CLL. Leuk Lymphoma 2003;44:Suppl:S4.
89. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001;98:3050-7.
90. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996;92:97-103.
91. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002;99:1030-7.
92. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003;102:2146-55.
93. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-83.
94. Orsini E, Foa R. Cytokines and regulatory molecules in the pathogenesis and clinical course of B-cell chronic lymphocytic leukemia. In: Cheson BD, ed. Chronic lymphoid leukemias. 2nd ed. New York: Marcel Dekker, 2001:127-60.
95. Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000;96:3181-7.
96. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004;104:788-94.
97. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 2002;43:461-6.
98. Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100:1795-801.
99. Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 2000;79:157-73.
100. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002;100:1404-9. [Erratum, Blood 2002;100:2291.]
101. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002;100:1404-9. [Erratum, Blood 2002;100:2291.]
102. Reed JC, Kitada S. Apoptosis dysregulation in chronic lymphocytic leukemia. In: Cheson BD, ed. Chronic lymphoid leukemias. 2nd ed. New York: Marcel Dekker, 2001:111-26.
103. Schiffer LM, Chanana AD, Cronkite EP, et al. Lymphocyte kinetics in chronic lymphocytic leukaemia (CLL) studied by ECIB. Br J Haematol 1969;17:408.
104. Theml H, Trepel G, Schick P, Kaboth W, Begemann H. Kinetics of lymphocytes in chronic lymphocytic leukemia: studies using continuous 3H-thymidine infusion in two patients. Blood 1973;42:623-36.
105. Messmer B, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest (in press).
106. Hultdin M, Rosenquist R, Thunberg U, et al. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer 2003;88:593-8.
107. Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004;103:375-82.
108. Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:3854-9.
109. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000;37:1141-9.
110. Ochsenbein AF, Fehr T, Lutz C, et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999;286:2156-9.
111. Keating MJ, Chiorazzi N, Messmer B, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2003:153-75.
112. Diaw L, Siwarski D, Coleman A, et al. Restricted immunoglobulin variable region (Ig V) gene expression accompanies secondary rearrangements of light chain Ig V genes in mouse plasmacytomas. J Exp Med 1999;190:1405-16.
113. Silverman GJ, Goldfien RD, Chen P, et al. Idiotypic and subgroup analysis of human monoclonal rheumatoid factors: implications for structural and genetic basis of autoantibodies in humans. J Clin Invest 1988;82:469-75.
114. Stevenson FK, Longhurst C, Chapman CJ, et al. Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. J Autoimmun 1993;6:809-25.
115. Pugh-Bernard AE, Silverman GJ, Cappione AJ, et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 2001;108:1061-70.
116. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002;100:635-9.
117. Ghia P, Prato G, Scielzo C, et al. Monoclonal CD5+ and CD5-B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004;103:2337-42.
118. Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002;100:2289-90.
119. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002;99:4087-93.
120. Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001;13:195-201.
121. Meffre E, Schaefer A, Wardemann H, Wilson P, Davis E, Nussenzweig MC. Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies. J Exp Med 2004;199:145-50.
122. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards immune competence. Trends Immunol 2003;24:343-9.